(S)-2-Amino-4,5,6,7-Tetrahydro-6-(Propylamino)Benzothiazole Dihydrochloride Monohydrate

The chemical entity (S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride monohydrate (CAS 191217-81-9, molecular formula C₁₀H₁₇N₃S·2HCl·H₂O, molecular weight 302.26 g/mol) is the active pharmaceutical ingredient identified as the (S)-enantiomer of pramipexole dihydrochloride monohydrate. The substance presents as a white to off-white crystalline powder with a melting point of 288–290 °C (decomposition) and a specific optical rotation of approximately −67° to −71° (c = 1, methanol) when measured at 589 nm and 20 °C. The monohydrate form is the stable hydrate under ambient conditions, containing one molecule of water of crystallisation per dihydrochloride salt unit, a stoichiometry that critically influences hygroscopicity behaviour, solid-state stability, and processing performance in solid dosage manufacture.

In solid-state characterisation by dynamic vapour sorption (DVS) at 25 °C, the monohydrate maintains a constant mass between 10% and 60% relative humidity, whereas the anhydrous dihydrochloride converts rapidly to the monohydrate upon exposure to humidities as low as 20% RH and continues to sorb water at higher RH without deliquescing until above 90% RH. The phase boundary between the anhydrate and monohydrate has been mapped by controlled humidity X-ray powder diffraction (XRPD); the anhydrate form becomes undetectable after 24 h at 75% RH, highlighting the necessity of tight environmental control when handling the non-hydrate form. Because the monohydrate is the equilibrium hydrate at room temperature and typical manufacturing humidities, it eliminates the risk of in-process conversion and the associated variability in water content, which for the monohydrate is specified to remain within a narrow range of 3.8–4.4% w/w when determined by Karl Fischer titration in accordance with USP〈921〉 Method Ia.

What Distinguishes the Monohydrate from the Anhydrous Form?

The anhydrous dihydrochloride salt is obtainable by vacuum drying the monohydrate at 105 °C until constant weight, but its practical use is hindered by rapid rehydration under standard processing atmospheres. Thermogravimetric analysis (TGA) of the monohydrate shows a single mass-loss step of approximately 6.0% between 40 °C and 120 °C, consistent with liberation of one water molecule and partial volatilisation of hydrogen chloride, while the anhydrous form displays no appreciable loss below 200 °C. The crystal structures differ: the monohydrate crystallises in a hydrogen-bonded network where water bridges chloride anions and the protonated amino groups, stabilising a denser packing motif that yields a lower true density (1.38 g/cm³) compared with the anhydrous phase (1.42 g/cm³). This difference impacts bulk density and flow indices when the material is processed directly in powder form. Furthermore, the presence of crystalline water in the monohydrate lattice modulates excipient compatibility; blends with anhydrous lactose stored at 40 °C/75% RH open conditions for 14 days showed no formation of Maillard reaction products, while identical blends containing the anhydrous salt developed detectable colouration, attributable to localised water uptake by the drug substance and subsequent reaction with the reducing sugar.

Specification Compliance Under USP and EP Monographs

The pharmacopoeial monographs for pramipexole dihydrochloride monohydrate (USP current edition; Ph. Eur. 2513) define a set of analytical release parameters that must be met for the material to be used as a drug substance. The table below summarises the critical quality attributes and the corresponding acceptance criteria, along with the reference compendial methods.

The chiral HPLC method employs a mobile phase of 0.05 M potassium phosphate buffer adjusted to pH 6.5 mixed with acetonitrile (95:5 v/v), with a flow rate of 0.8 mL/min on a 150 × 4.6 mm chiral glycoprotein column (L41). Under these conditions, the (R)-enantiomer elutes at a relative retention time of approximately 1.2 with respect to the (S)-peak. A limit of quantitation below 0.05% is routinely achieved, allowing reliable detection of chiral impurity at one-half of the specified threshold. For dissolution testing of finished tablets containing the monohydrate, USP〈711〉 Apparatus 2 (paddle) operated at 50 rpm in 500 mL of 0.1 N hydrochloric acid at 37 °C is the official procedure; acceptance at stage S1 requires not less than 80% (Q) of the labelled amount dissolved within 30 minutes.

Assessing Enantiomeric Purity and Its Impact on Dopamine D3 Selectivity

The (S)-enantiomer of the benzothiazole derivative exhibits pronounced affinity for the dopamine D3 receptor subtype, with a reported inhibition constant (K_i) of approximately 0.5 nM, while its affinity for the D2 receptor is roughly 7 nM, yielding a D3/D2 selectivity ratio of about 0.07. This preferential binding to the D3 autoreceptor accounts for the therapeutic utility of the (S)-isomer in Parkinson’s disease and restless legs syndrome at doses that limit D2-mediated peripheral side effects. In contrast, the (R)-enantiomer displays drastically diminished receptor engagement, with K_i values exceeding 2,000 nM for D2 and 5,000 nM for D3, rendering it pharmacologically irrelevant at the concentrations reached during clinical use. The profound difference stems from the orientation of the propylamino side chain; molecular docking studies indicate that only the (S)-configuration permits simultaneous hydrogen bonding of the aminothiazole moiety to serine residues in transmembrane helix 5 and hydrophobic packing of the propyl chain into the accessory binding pocket of the D3 receptor.

The pharmacopoeial limit of ≤ 0.1% for the (R)-enantiomer is not arbitrary. Competitive binding experiments using human recombinant receptors demonstrate that a 0.5% contamination of the (R)-isomer in a sample of (S)-pramipexole increases the apparent D3 K_i by less than 5%, but above 1% contamination the displacement curve begins to show a detectable two-site component, indicating a mixed population of high- and low-affinity sites. At 5% (R)-content, the measured K_i for D3 exceeds 12 nM, and the selectivity over D2 collapses to a ratio of 1.5. Therefore, commercial bulk drug substance is routinely controlled to enantiomeric purity not less than 99.9% area, as verified by the validated chiral HPLC method.

When the (R)-Enantiomer Contamination Exceeds 0.5%, Binding Selectivity Collapses

Formulations manufactured with drug substance batches approaching the 0.5% chiral impurity threshold have been examined in in vitro functional assays measuring [³⁵S]GTPγS binding at CHO cells stably expressing human D3 receptors. At a test concentration of 10 nM (S)-enantiomer, the addition of 0.5% (R)-isomer caused a 12% reduction in maximum stimulation compared with enantiopure material, and addition of 2% reduced the signal by 38%. This non-linear attenuation arises because the (R)-isomer behaves as a competitive antagonist at D3 receptors with a K_b of approximately 1.8 μM, meaning that at nanomolar concentrations of the (S)-agonist, even low levels of the antagonist enantiomer begin to occupy a significant fraction of receptors. Consequently, strict enantiomeric control is a quality attribute with direct pharmacodynamic consequence, and the single-enantiomer monohydrate salt is the only form that permits reliable clinical dosing.

Direct compression of low-dose tablets containing the monohydrate at strengths of 0.125 mg, 0.25 mg, 0.5 mg, 1.0 mg, and 1.5 mg of pramipexole base requires particular attention to particle size distribution of the drug substance to achieve content uniformity compliant with USP〈905〉. The monohydrate as received typically exhibits a D₅₀ of 15–25 μm and a D₉₀ below 80 μm. Blending studies on 20 kg scale using a bin blender operated at 25 rpm for 15 minutes demonstrated that a pre-blend of the drug substance with a portion of microcrystalline cellulose (Avicel PH-102) in a geometric dilution ratio of 1:5 yields a final blend uniformity with an RSD of ≤ 2.8% for the 0.125 mg strength. Over-milling of the monohydrate to a D₅₀ below 10 μm increases the specific surface area to above 2.5 m²/g and promotes electrostatic adhesion to metal surfaces of the rotary tablet press, resulting in weight variability excursions beyond ±5% of target and occasional punch filming. Humidity must be maintained at 30–45% RH in the compression suite to prevent conversion of any residual anhydrate domains generated during energetic milling; the monohydrate itself does not dehydrate until the temperature exceeds 40 °C at ambient RH, making it robust under standard processing conditions.

Distinctions from Ergot-Derived Agonists and Structural Analogs

Unlike the ergot alkaloid dopamine agonists (bromocriptine, pergolide, cabergoline), the benzothiazole structure lacks the tetracyclic ergoline skeleton, eliminating the risk of ergotism-like fibrotic adverse reactions mediated by 5-HT_2B receptor agonism. The (S)-aminothiazole has negligible affinity for 5-HT_2B (K_i > 10,000 nM) and is therefore not associated with retroperitoneal, pulmonary, or pericardial fibrosis even under long-term administration. Compared with ropinirole, another non-ergoline D2/D3 agonist, the (S)-monohydrate exhibits more pronounced D3 selectivity. The table below collates published receptor binding affinities for the two enantiomers of the benzothiazole and for ropinirole hydrochloride.

*Reported inhibition constants from in vitro radioligand displacement assays using human cloned receptors expressed in CHO cells; values are representative of multiple published datasets.

The higher D3 preference of the (S)-benzothiazole translates into a lower effective dose for symptom control in early Parkinson’s disease and reduced dopaminergic adverse effects relative to ropinirole at comparable D2 occupancy. The monohydrate salt further provides a defined hydration stoichiometry that eliminates water content variability during manufacture, extending shelf-life and simplifying international regulatory filings under ICH Q1A(R2) and Q6A guidelines.

Reconstitution of the monohydrate in aqueous media at concentrations up to 5 mg/mL produces a solution with pH 2.8–3.2 due to the dihydrochloride salt. This pH precludes co-formulation in liquid dosage forms with acid-labile viscosity modifiers or with neutral-pH buffer systems unless the excipient stability is verified by stressed degradation studies at 40 °C/75% RH for a minimum of 14 days. Published data for this specific configuration confirm that hydroxypropyl methylcellulose E5 and sodium carboxymethylcellulose maintain >95% of initial viscosity when stored with the drug substance under these conditions, making them suitable for suspension vehicles if needed for specialised paediatric or enteral administration.